Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.
Identifieur interne : 002474 ( PubMed/Checkpoint ); précédent : 002473; suivant : 002475Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.
Auteurs : T. Würdinger [Pays-Bas] ; M H Verheije ; K. Broen ; B J Bosch ; B J Haijema ; C A M. De Haan ; V W Van Beusechem ; W R Gerritsen ; P J M. RottierSource :
- Journal of virology [ 0022-538X ] ; 2005.
Descripteurs français
- KwdFr :
- Animaux, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (), Glycoprotéines membranaires (physiologie), Humains, Infections à coronavirus (immunologie), Infections à coronavirus (métabolisme), Protéines de l'enveloppe virale (), Protéines de l'enveloppe virale (physiologie), Récepteurs ErbB (métabolisme), Souris, Virus de l'hépatite murine (physiologie).
- MESH :
- immunologie : Infections à coronavirus.
- métabolisme : Infections à coronavirus, Récepteurs ErbB.
- physiologie : Glycoprotéines membranaires, Protéines de l'enveloppe virale, Virus de l'hépatite murine.
- Animaux, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires, Humains, Protéines de l'enveloppe virale, Souris.
English descriptors
- KwdEn :
- Animals, Coronavirus Infections (immunology), Coronavirus Infections (metabolism), ErbB Receptors (metabolism), Humans, Membrane Glycoproteins (chemistry), Membrane Glycoproteins (physiology), Mice, Murine hepatitis virus (physiology), Spike Glycoprotein, Coronavirus, Viral Envelope Proteins (chemistry), Viral Envelope Proteins (physiology).
- MESH :
- chemical , chemistry : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical , metabolism : ErbB Receptors.
- immunology : Coronavirus Infections.
- metabolism : Coronavirus Infections.
- chemical , physiology : Membrane Glycoproteins, Murine hepatitis virus, Viral Envelope Proteins.
- Animals, Humans, Mice, Spike Glycoprotein, Coronavirus.
Abstract
The mouse hepatitis coronavirus (MHV) infects murine cells by binding of its spike (S) protein to murine CEACAM1a. The N-terminal part of this cellular receptor (soR) is sufficient for S binding and for subsequent induction of the conformational changes required for virus-cell membrane fusion. Here we analyzed whether these characteristics can be used to redirect MHV to human cancer cells. To this end, the soR domain was coupled to single-chain monoclonal antibody 425, which is directed against the human epidermal growth factor receptor (EGFR), resulting in a bispecific adapter protein (soR-425). The soR and soR-425 proteins, both produced with the vaccinia virus system, were able to neutralize MHV infection of murine LR7 cells. However, only soR-425 was able to target MHV to human EGFR-expressing cancer cells. Interestingly, the targeted infections induced syncytium formation. Furthermore, the soR-425-mediated infections were blocked by heptad repeat-mimicking peptides, indicating that virus entry requires the regular S protein fusion process. We conclude that the specific spike-binding property of the CEACAM1a N-terminal fragment can be exploited to direct the virus to selected cells by linking it to a moiety able to bind a receptor on those cells. This approach might be useful in the development of tumor-targeted coronaviruses.
DOI: 10.1128/JVI.79.24.15314-15322.2005
PubMed: 16306602
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:16306602Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.</title><author><name sortKey="Wurdinger, T" sort="Wurdinger, T" uniqKey="Wurdinger T" first="T" last="Würdinger">T. Würdinger</name><affiliation wicri:level="4"><nlm:affiliation>Virology Division, Department of Infectious Diseases & Immunology, Utrecht University, 3584 CL Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Virology Division, Department of Infectious Diseases & Immunology, Utrecht University, 3584 CL Utrecht</wicri:regionArea><orgName type="university">Université d'Utrecht</orgName><placeName><settlement type="city">Utrecht</settlement><region nuts="2">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Verheije, M H" sort="Verheije, M H" uniqKey="Verheije M" first="M H" last="Verheije">M H Verheije</name></author><author><name sortKey="Broen, K" sort="Broen, K" uniqKey="Broen K" first="K" last="Broen">K. Broen</name></author><author><name sortKey="Bosch, B J" sort="Bosch, B J" uniqKey="Bosch B" first="B J" last="Bosch">B J Bosch</name></author><author><name sortKey="Haijema, B J" sort="Haijema, B J" uniqKey="Haijema B" first="B J" last="Haijema">B J Haijema</name></author><author><name sortKey="De Haan, C A M" sort="De Haan, C A M" uniqKey="De Haan C" first="C A M" last="De Haan">C A M. De Haan</name></author><author><name sortKey="Van Beusechem, V W" sort="Van Beusechem, V W" uniqKey="Van Beusechem V" first="V W" last="Van Beusechem">V W Van Beusechem</name></author><author><name sortKey="Gerritsen, W R" sort="Gerritsen, W R" uniqKey="Gerritsen W" first="W R" last="Gerritsen">W R Gerritsen</name></author><author><name sortKey="Rottier, P J M" sort="Rottier, P J M" uniqKey="Rottier P" first="P J M" last="Rottier">P J M. Rottier</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16306602</idno><idno type="pmid">16306602</idno><idno type="doi">10.1128/JVI.79.24.15314-15322.2005</idno><idno type="wicri:Area/PubMed/Corpus">002433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002433</idno><idno type="wicri:Area/PubMed/Curation">002433</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002433</idno><idno type="wicri:Area/PubMed/Checkpoint">002474</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002474</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.</title><author><name sortKey="Wurdinger, T" sort="Wurdinger, T" uniqKey="Wurdinger T" first="T" last="Würdinger">T. Würdinger</name><affiliation wicri:level="4"><nlm:affiliation>Virology Division, Department of Infectious Diseases & Immunology, Utrecht University, 3584 CL Utrecht, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Virology Division, Department of Infectious Diseases & Immunology, Utrecht University, 3584 CL Utrecht</wicri:regionArea><orgName type="university">Université d'Utrecht</orgName><placeName><settlement type="city">Utrecht</settlement><region nuts="2">Utrecht (province)</region></placeName></affiliation></author><author><name sortKey="Verheije, M H" sort="Verheije, M H" uniqKey="Verheije M" first="M H" last="Verheije">M H Verheije</name></author><author><name sortKey="Broen, K" sort="Broen, K" uniqKey="Broen K" first="K" last="Broen">K. Broen</name></author><author><name sortKey="Bosch, B J" sort="Bosch, B J" uniqKey="Bosch B" first="B J" last="Bosch">B J Bosch</name></author><author><name sortKey="Haijema, B J" sort="Haijema, B J" uniqKey="Haijema B" first="B J" last="Haijema">B J Haijema</name></author><author><name sortKey="De Haan, C A M" sort="De Haan, C A M" uniqKey="De Haan C" first="C A M" last="De Haan">C A M. De Haan</name></author><author><name sortKey="Van Beusechem, V W" sort="Van Beusechem, V W" uniqKey="Van Beusechem V" first="V W" last="Van Beusechem">V W Van Beusechem</name></author><author><name sortKey="Gerritsen, W R" sort="Gerritsen, W R" uniqKey="Gerritsen W" first="W R" last="Gerritsen">W R Gerritsen</name></author><author><name sortKey="Rottier, P J M" sort="Rottier, P J M" uniqKey="Rottier P" first="P J M" last="Rottier">P J M. Rottier</name></author></analytic><series><title level="j">Journal of virology</title><idno type="ISSN">0022-538X</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Coronavirus Infections (immunology)</term><term>Coronavirus Infections (metabolism)</term><term>ErbB Receptors (metabolism)</term><term>Humans</term><term>Membrane Glycoproteins (chemistry)</term><term>Membrane Glycoproteins (physiology)</term><term>Mice</term><term>Murine hepatitis virus (physiology)</term><term>Spike Glycoprotein, Coronavirus</term><term>Viral Envelope Proteins (chemistry)</term><term>Viral Envelope Proteins (physiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires ()</term><term>Glycoprotéines membranaires (physiologie)</term><term>Humains</term><term>Infections à coronavirus (immunologie)</term><term>Infections à coronavirus (métabolisme)</term><term>Protéines de l'enveloppe virale ()</term><term>Protéines de l'enveloppe virale (physiologie)</term><term>Récepteurs ErbB (métabolisme)</term><term>Souris</term><term>Virus de l'hépatite murine (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>ErbB Receptors</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Infections à coronavirus</term><term>Récepteurs ErbB</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Glycoprotéines membranaires</term><term>Protéines de l'enveloppe virale</term><term>Virus de l'hépatite murine</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Membrane Glycoproteins</term><term>Murine hepatitis virus</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Mice</term><term>Spike Glycoprotein, Coronavirus</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Glycoprotéine de spicule des coronavirus</term><term>Glycoprotéines membranaires</term><term>Humains</term><term>Protéines de l'enveloppe virale</term><term>Souris</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The mouse hepatitis coronavirus (MHV) infects murine cells by binding of its spike (S) protein to murine CEACAM1a. The N-terminal part of this cellular receptor (soR) is sufficient for S binding and for subsequent induction of the conformational changes required for virus-cell membrane fusion. Here we analyzed whether these characteristics can be used to redirect MHV to human cancer cells. To this end, the soR domain was coupled to single-chain monoclonal antibody 425, which is directed against the human epidermal growth factor receptor (EGFR), resulting in a bispecific adapter protein (soR-425). The soR and soR-425 proteins, both produced with the vaccinia virus system, were able to neutralize MHV infection of murine LR7 cells. However, only soR-425 was able to target MHV to human EGFR-expressing cancer cells. Interestingly, the targeted infections induced syncytium formation. Furthermore, the soR-425-mediated infections were blocked by heptad repeat-mimicking peptides, indicating that virus entry requires the regular S protein fusion process. We conclude that the specific spike-binding property of the CEACAM1a N-terminal fragment can be exploited to direct the virus to selected cells by linking it to a moiety able to bind a receptor on those cells. This approach might be useful in the development of tumor-targeted coronaviruses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16306602</PMID><DateCompleted><Year>2006</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN><JournalIssue CitedMedium="Print"><Volume>79</Volume><Issue>24</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of virology</Title><ISOAbbreviation>J. Virol.</ISOAbbreviation></Journal><ArticleTitle>Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.</ArticleTitle><Pagination><MedlinePgn>15314-22</MedlinePgn></Pagination><Abstract><AbstractText>The mouse hepatitis coronavirus (MHV) infects murine cells by binding of its spike (S) protein to murine CEACAM1a. The N-terminal part of this cellular receptor (soR) is sufficient for S binding and for subsequent induction of the conformational changes required for virus-cell membrane fusion. Here we analyzed whether these characteristics can be used to redirect MHV to human cancer cells. To this end, the soR domain was coupled to single-chain monoclonal antibody 425, which is directed against the human epidermal growth factor receptor (EGFR), resulting in a bispecific adapter protein (soR-425). The soR and soR-425 proteins, both produced with the vaccinia virus system, were able to neutralize MHV infection of murine LR7 cells. However, only soR-425 was able to target MHV to human EGFR-expressing cancer cells. Interestingly, the targeted infections induced syncytium formation. Furthermore, the soR-425-mediated infections were blocked by heptad repeat-mimicking peptides, indicating that virus entry requires the regular S protein fusion process. We conclude that the specific spike-binding property of the CEACAM1a N-terminal fragment can be exploited to direct the virus to selected cells by linking it to a moiety able to bind a receptor on those cells. This approach might be useful in the development of tumor-targeted coronaviruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Würdinger</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Virology Division, Department of Infectious Diseases & Immunology, Utrecht University, 3584 CL Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verheije</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author><Author ValidYN="Y"><LastName>Broen</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bosch</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>Haijema</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>de Haan</LastName><ForeName>C A M</ForeName><Initials>CA</Initials></Author><Author ValidYN="Y"><LastName>van Beusechem</LastName><ForeName>V W</ForeName><Initials>VW</Initials></Author><Author ValidYN="Y"><LastName>Gerritsen</LastName><ForeName>W R</ForeName><Initials>WR</Initials></Author><Author ValidYN="Y"><LastName>Rottier</LastName><ForeName>P J M</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Virol</MedlineTA><NlmUniqueID>0113724</NlmUniqueID><ISSNLinking>0022-538X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006517" MajorTopicYN="N">Murine hepatitis virus</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16306602</ArticleId><ArticleId IdType="pii">79/24/15314</ArticleId><ArticleId IdType="doi">10.1128/JVI.79.24.15314-15322.2005</ArticleId><ArticleId IdType="pmc">PMC1316040</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Virol. 1997 Apr;71(4):3129-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9060676</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2005 Oct;79(20):12742-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16188977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1998 Mar;72(3):1941-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9499047</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):7063-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9618539</ArticleId></ArticleIdList></Reference><Reference><Citation>FEBS Lett. 1998 Jul 31;432(1-2):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9710248</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2005 Jan 25;44(3):947-58</Citation><ArticleIdList><ArticleId IdType="pubmed">15654751</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Ther. 2005 Apr;11(4):617-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15771964</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2005 Sep;12(18):1394-404</Citation><ArticleIdList><ArticleId IdType="pubmed">15843808</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2000 Feb;74(3):1393-406</Citation><ArticleIdList><ArticleId IdType="pubmed">10627550</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Gene Ther. 2000 Jun;7(6):901-4</Citation><ArticleIdList><ArticleId IdType="pubmed">10880021</ArticleId></ArticleIdList></Reference><Reference><Citation>Crit Rev Oncol Hematol. 2001 Jun;38(3):177-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11369253</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biotechnol. 2001 Jul 12;88(3):183-204</Citation><ArticleIdList><ArticleId IdType="pubmed">11434966</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 1999 Nov 1;252(2):243-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11501563</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 2002 Jan 15;62(2):609-16</Citation><ArticleIdList><ArticleId IdType="pubmed">11809717</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gen Virol. 2002 Mar;83(Pt 3):491-502</Citation><ArticleIdList><ArticleId IdType="pubmed">11842243</ArticleId></ArticleIdList></Reference><Reference><Citation>EMBO J. 2002 May 1;21(9):2076-86</Citation><ArticleIdList><ArticleId IdType="pubmed">11980704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2002 Dec;76(23):11819-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12414924</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Jan;77(2):830-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12502799</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Jan;77(2):841-50</Citation><ArticleIdList><ArticleId IdType="pubmed">12502800</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Med. 2003 Jan;9(1):135-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12514727</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Gene Ther. 2002 Dec;9(12):961-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12522435</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Apr;77(8):4528-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12663759</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Gene Ther. 2003 Aug;10(8):583-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12872139</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gene Ther. 2003 Nov;10(23):1982-91</Citation><ArticleIdList><ArticleId IdType="pubmed">14528322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2003 Nov;77(21):11312-23</Citation><ArticleIdList><ArticleId IdType="pubmed">14557617</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Jan;78(1):216-23</Citation><ArticleIdList><ArticleId IdType="pubmed">14671103</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2004 Sep;78(18):10156-65</Citation><ArticleIdList><ArticleId IdType="pubmed">15331748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1981 Nov;40(2):350-7</Citation><ArticleIdList><ArticleId IdType="pubmed">6275093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1985 Dec;56(3):912-20</Citation><ArticleIdList><ArticleId IdType="pubmed">2999444</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell. 1989 Mar 10;56(5):855-65</Citation><ArticleIdList><ArticleId IdType="pubmed">2538245</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1990 Sep;87(17):6743-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2204064</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5533-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1648219</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1991 Dec;65(12):6881-91</Citation><ArticleIdList><ArticleId IdType="pubmed">1719235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1992 May;66(5):2807-13</Citation><ArticleIdList><ArticleId IdType="pubmed">1560525</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1992 Dec;66(12):7420-8</Citation><ArticleIdList><ArticleId IdType="pubmed">1279203</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1993 Jan;67(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8380065</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1716-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8383324</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1995 Jan;69(1):543-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7983753</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 1997 Jul;71(7):5148-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9188582</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country><region><li>Utrecht (province)</li></region><settlement><li>Utrecht</li></settlement><orgName><li>Université d'Utrecht</li></orgName></list><tree><noCountry><name sortKey="Bosch, B J" sort="Bosch, B J" uniqKey="Bosch B" first="B J" last="Bosch">B J Bosch</name><name sortKey="Broen, K" sort="Broen, K" uniqKey="Broen K" first="K" last="Broen">K. Broen</name><name sortKey="De Haan, C A M" sort="De Haan, C A M" uniqKey="De Haan C" first="C A M" last="De Haan">C A M. De Haan</name><name sortKey="Gerritsen, W R" sort="Gerritsen, W R" uniqKey="Gerritsen W" first="W R" last="Gerritsen">W R Gerritsen</name><name sortKey="Haijema, B J" sort="Haijema, B J" uniqKey="Haijema B" first="B J" last="Haijema">B J Haijema</name><name sortKey="Rottier, P J M" sort="Rottier, P J M" uniqKey="Rottier P" first="P J M" last="Rottier">P J M. Rottier</name><name sortKey="Van Beusechem, V W" sort="Van Beusechem, V W" uniqKey="Van Beusechem V" first="V W" last="Van Beusechem">V W Van Beusechem</name><name sortKey="Verheije, M H" sort="Verheije, M H" uniqKey="Verheije M" first="M H" last="Verheije">M H Verheije</name></noCountry><country name="Pays-Bas"><region name="Utrecht (province)"><name sortKey="Wurdinger, T" sort="Wurdinger, T" uniqKey="Wurdinger T" first="T" last="Würdinger">T. Würdinger</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002474 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002474 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:16306602
|texte= Soluble receptor-mediated targeting of mouse hepatitis coronavirus to the human epidermal growth factor receptor.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:16306602" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |